Novel Ultra-low-dose Chest CT Technique to Screen for Pulmonary Arteriovenous Malformations in Pediatric Patients With Hereditary Hemorrhagic Teleangiectasia
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Mayo Clinic
- Enrollment
- 3
- Locations
- 2
- Primary Endpoint
- Ultra-low dose images PAVM detection
Study Overview
Brief Summary
This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 1 Year to 17 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Ages 1 to 17 years
- •Diagnosed with positive HHT causing mutations or based on Curacao criteria
Exclusion Criteria
- •Acute respiratory distress
- •Unstable cardiovascular status
- •Pneumothorax, hemoptysis
- •Pulmonary edema
- •Pulmonary emboli
- •Fractured ribs or other chest trauma
- •Recent bronchoscopy
- •Lung transplantation
Arms & Interventions
Low-dose contrast-enhanced chest CT exam
Subjects will undergo a low-dose contrast-enhanced chest CT exam with coverage from the neck base through the lungs to the upper abdomen on a third-generation dual-source CT scanner as part of their routine clinical visit based on current guidelines.
Intervention: Ultra-low dose chest CT (Diagnostic Test)
Outcomes
Primary Outcomes
Ultra-low dose images PAVM detection
Time Frame: Baseline
Number of images detecting PAVM using the ultra-low dose images (50% or lower compared to the full dose)
Secondary Outcomes
No secondary outcomes reported
Investigators
Nadir Demirel
Principal Investigator
Mayo Clinic